556.2

+0.13%↑

SANES

11.106

+0.98%↑

SAF

346.2

+0.9%↑

BBVA

20.03

0%↓

BNP

96.66

+0.32%↑

556.2

+0.13%↑

SANES

11.106

+0.98%↑

SAF

346.2

+0.9%↑

BBVA

20.03

0%↓

BNP

96.66

+0.32%↑

556.2

+0.13%↑

SANES

11.106

+0.98%↑

SAF

346.2

+0.9%↑

BBVA

20.03

0%↓

BNP

96.66

+0.32%↑

556.2

+0.13%↑

SANES

11.106

+0.98%↑

SAF

346.2

+0.9%↑

BBVA

20.03

0%↓

BNP

96.66

+0.32%↑

556.2

+0.13%↑

SANES

11.106

+0.98%↑

SAF

346.2

+0.9%↑

BBVA

20.03

0%↓

BNP

96.66

+0.32%↑

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Atidarymo kaina

1.322 -0.3

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.288

Max

1.358

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M
Pardavimai	515K
Pelno marža	-1,005.243
Darbuotojai	36
EBITDA	-2.5M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	88M
Ankstesnė atidarymo kaina	1.62
Ankstesnė uždarymo kaina	1.322

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-25 23:25; UTC

Karštos akcijos

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

2026-02-25 23:15; UTC

Uždarbis

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

2026-02-25 23:54; UTC

Rinkos pokalbiai

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

2026-02-25 23:47; UTC

Uždarbis

Ferrovial 4Q Net EUR197M >FER.MC

2026-02-25 23:45; UTC

Uždarbis

Ferrovial 4Q Rev EUR2.72B >FER.MC

2026-02-25 23:42; UTC

Uždarbis

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

2026-02-25 23:38; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Company's Business Operations Remain Normal >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY EPS CNY47.67 >TCOM

2026-02-25 23:06; UTC

Uždarbis

Correction to Nvidia Fourth Quarter Results Article -- WSJ

2026-02-25 23:01; UTC

Uždarbis

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

2026-02-25 23:00; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-02-25 23:00; UTC

Rinkos pokalbiai

Uždarbis

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

2026-02-25 22:56; UTC

Rinkos pokalbiai

Uždarbis

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

2026-02-25 22:43; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

2026-02-25 22:40; UTC

Rinkos pokalbiai

Uždarbis

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

2026-02-25 22:40; UTC

Uždarbis

Karoon Energy Says Search for New CFO Well Advanced

2026-02-25 22:39; UTC

Uždarbis

Karoon Energy Says CFO Ray Church to Leave Company

2026-02-25 22:39; UTC

Uždarbis

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

2026-02-25 22:38; UTC

Uždarbis

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių AB Science SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.